---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-122296"
form_type: "8-K"
ticker: "ALEC"
cik: "0001653087"
company_name: "Alector, Inc."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:36:57.211969+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Alector reports Q3 net loss $42.2M ($0.43/share); cash $457.2M funds through 2026

## Summary
- Cash, cash equivalents, investments $457.2M as of Sep 30, 2024, sufficient to fund operations through 2026.
- Q3 2024 net loss $42.2M ($0.43 per share) vs $44.5M ($0.53) in Q3 2023; collaboration revenue $15.3M, up from $9.1M.
- R&D expenses $48.0M driven by AL101 Phase 2 start; G&A $15.8M includes impairment from lab transition.
- FY 2024 guidance: collaboration rev $60-70M, R&D $210-220M, G&A $60-70M.
- INVOKE-2 (AL002) Phase 2 data due in 2024; INFRONT-3 (latozinemab) top-line late 2025/early 2026; PROGRESS-AD >1/3 enrolled.

## SEC filing metadata
- accession: 0000950170-24-122296
- form_type: 8-K
- ticker: ALEC
- cik: 0001653087
- company_name: Alector, Inc.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1653087/000095017024122296/0000950170-24-122296-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1653087/000095017024122296/alec-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-122296
- JSON: https://secwatch.observer/filing/0000950170-24-122296.json
- Plain text: https://secwatch.observer/filing/0000950170-24-122296.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.